Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer
Prostate cancer is an androgen-driven tumor. Different prostate cancer therapies consequently focus on blocking the androgen receptor pathway. Clinical studies reported tumor resistance mechanisms by reactivating and bypassing the androgen pathway. Preclinical models allowed the identification, conf...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/4/915 |
| _version_ | 1797395708575219712 |
|---|---|
| author | Wout Devlies Florian Handle Gaëtan Devos Steven Joniau Frank Claessens |
| author_facet | Wout Devlies Florian Handle Gaëtan Devos Steven Joniau Frank Claessens |
| author_sort | Wout Devlies |
| collection | DOAJ |
| description | Prostate cancer is an androgen-driven tumor. Different prostate cancer therapies consequently focus on blocking the androgen receptor pathway. Clinical studies reported tumor resistance mechanisms by reactivating and bypassing the androgen pathway. Preclinical models allowed the identification, confirmation, and thorough study of these pathways. This review looks into the current and future role of preclinical models to understand resistance to androgen receptor-targeted therapies. Increasing knowledge on this resistance will greatly improve insights into tumor pathophysiology and future treatment strategies in prostate cancer. |
| first_indexed | 2024-03-09T00:38:29Z |
| format | Article |
| id | doaj.art-6e7a09c086b84359ac1146d79f030236 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T00:38:29Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-6e7a09c086b84359ac1146d79f0302362023-12-11T17:57:58ZengMDPI AGCancers2072-66942021-02-0113491510.3390/cancers13040915Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate CancerWout Devlies0Florian Handle1Gaëtan Devos2Steven Joniau3Frank Claessens4Laboratory of Molecular Endocrinology, KU Leuven, 3000 Leuven, BelgiumDivision of Experimental Urology, Department of Urology, Medical University of Innsbruck, 6020 Innsbruck, AustriaDepartment of Urology, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Urology, University Hospitals Leuven, 3000 Leuven, BelgiumLaboratory of Molecular Endocrinology, KU Leuven, 3000 Leuven, BelgiumProstate cancer is an androgen-driven tumor. Different prostate cancer therapies consequently focus on blocking the androgen receptor pathway. Clinical studies reported tumor resistance mechanisms by reactivating and bypassing the androgen pathway. Preclinical models allowed the identification, confirmation, and thorough study of these pathways. This review looks into the current and future role of preclinical models to understand resistance to androgen receptor-targeted therapies. Increasing knowledge on this resistance will greatly improve insights into tumor pathophysiology and future treatment strategies in prostate cancer.https://www.mdpi.com/2072-6694/13/4/915preclinical modelsandrogen receptorprostate cancerhormone treatmentARSIARTA |
| spellingShingle | Wout Devlies Florian Handle Gaëtan Devos Steven Joniau Frank Claessens Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer Cancers preclinical models androgen receptor prostate cancer hormone treatment ARSI ARTA |
| title | Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer |
| title_full | Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer |
| title_fullStr | Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer |
| title_full_unstemmed | Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer |
| title_short | Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer |
| title_sort | preclinical models in prostate cancer resistance to ar targeting therapies in prostate cancer |
| topic | preclinical models androgen receptor prostate cancer hormone treatment ARSI ARTA |
| url | https://www.mdpi.com/2072-6694/13/4/915 |
| work_keys_str_mv | AT woutdevlies preclinicalmodelsinprostatecancerresistancetoartargetingtherapiesinprostatecancer AT florianhandle preclinicalmodelsinprostatecancerresistancetoartargetingtherapiesinprostatecancer AT gaetandevos preclinicalmodelsinprostatecancerresistancetoartargetingtherapiesinprostatecancer AT stevenjoniau preclinicalmodelsinprostatecancerresistancetoartargetingtherapiesinprostatecancer AT frankclaessens preclinicalmodelsinprostatecancerresistancetoartargetingtherapiesinprostatecancer |